EFFORT: Phase II Study of the WEE1 Inhibitor Adavosertib ± Olaparib in PARPi-Resistant Ovarian Cancer

Experts review key data for ovarian, endometrial, and cervical cancers from the 2022 SGO, ASCO, ESMO, IGCS, and ESGO meetings, from Clinical Care Options (CCO)

Susana Banerjee, MBBS, MA, PhD, FRCP Jubilee Brown, MD Elisabeth Diver, MD Alexandra Leary, MD, PhD Domenica Lorusso, MD, PhD David Scott Miller, MD, FACOG, FACS Mansoor Raza Mirza, MD Prof Isabelle Ray-Coquard, MD, PhD Angeles Alvarez Secord, MD, MHSc Ignace Vergote, MD, PhD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: January 23, 2023 Expired: January 22, 2024

Expert commentary on HRD testing, PARP inhibitor, and quality-of-life studies in rare ovarian cancer from the 2022 ESGO Congress, from Clinical Care Options (CCO)

Prof Isabelle Ray-Coquard, MD, PhD Ignace Vergote, MD, PhD Released: December 2, 2022

Experts provide their thoughts on key data in breast, gynecologic, renal cell, urothelial, lung, hepatobiliary, and skin cancers presented at the 2022 ESMO Congress, from Clinical Care Options (CCO)

Nicoletta Colombo, MD Robert Motzer, MD Sapna P. Patel, MD David Planchard, MD, PhD Elizabeth R. Plimack, MD, MS Rachna Shroff, MD, MS Sara Tolaney, MD, MPH Physicians: maximum of 1.25 AMA PRA Category 1 Credits™ Released: November 14, 2022 Expired: November 13, 2023

Downloadable slideset updated with highlights of key gynecologic oncology studies presented at conferences throughout 2022, from Clinical Care Options (CCO)

Susana Banerjee, MBBS, MA, PhD, FRCP Jubilee Brown, MD Elisabeth Diver, MD Alexandra Leary, MD, PhD Domenica Lorusso, MD, PhD David Scott Miller, MD, FACOG, FACS Mansoor Raza Mirza, MD Prof Isabelle Ray-Coquard, MD, PhD Angeles Alvarez Secord, MD, MHSc Ignace Vergote, MD, PhD Released: November 10, 2022